Phage-derived anti-idiotype and anti-YTE antibodies in development of MK-1654 pharmacokinetic and immune response assays
Background: MK-1654 is a fully human monoclonal antibody with YTE mutations currently in phase III clinical trials for prophylactic use in protecting infants from human respiratory syncytial virus infection. Materials & methods: We generated anti-idiotype (anti-ID) and anti-YTE antibodies against MK-1654 by panning with MorphoSys HuCal phage libraries, and used the antibodies in the development of MK-1654 pharmacokinetic (PK) and immune response (IR) assays. Results: Detection of MK-1654 in nonhuman primate and human nasal wash samples showed combined use of anti-ID and anti-YTE antibodies can deliver desired sensitivity and accuracy in PK studies. IR studies showed anti-ID can serve as suitable positive control in neutralizing antibody assays. Conclusion: Phage-derived anti-IDs and anti-YTEs are suitable for PK and IR assays.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:15 |
|---|---|
| Enthalten in: |
Bioanalysis - 15(2023), 16 vom: 29. Aug., Seite 1049-1067 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Li, April [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Anti-YTE antibody |
|---|
| Anmerkungen: |
Date Completed 07.09.2023 Date Revised 07.09.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.4155/bio-2023-0081 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM360154018 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM360154018 | ||
| 003 | DE-627 | ||
| 005 | 20231226082415.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.4155/bio-2023-0081 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1200.xml |
| 035 | |a (DE-627)NLM360154018 | ||
| 035 | |a (NLM)37515532 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Li, April |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Phage-derived anti-idiotype and anti-YTE antibodies in development of MK-1654 pharmacokinetic and immune response assays |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 07.09.2023 | ||
| 500 | |a Date Revised 07.09.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Background: MK-1654 is a fully human monoclonal antibody with YTE mutations currently in phase III clinical trials for prophylactic use in protecting infants from human respiratory syncytial virus infection. Materials & methods: We generated anti-idiotype (anti-ID) and anti-YTE antibodies against MK-1654 by panning with MorphoSys HuCal phage libraries, and used the antibodies in the development of MK-1654 pharmacokinetic (PK) and immune response (IR) assays. Results: Detection of MK-1654 in nonhuman primate and human nasal wash samples showed combined use of anti-ID and anti-YTE antibodies can deliver desired sensitivity and accuracy in PK studies. IR studies showed anti-ID can serve as suitable positive control in neutralizing antibody assays. Conclusion: Phage-derived anti-IDs and anti-YTEs are suitable for PK and IR assays | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a anti-YTE antibody | |
| 650 | 4 | |a anti-idiotype antibody | |
| 650 | 4 | |a antidrug antibody | |
| 650 | 4 | |a immune response | |
| 650 | 4 | |a neutralizing antibody | |
| 650 | 4 | |a phage display | |
| 650 | 4 | |a pharmacokinetic | |
| 650 | 7 | |a MK-1654 |2 NLM | |
| 650 | 7 | |a Antibodies, Neutralizing |2 NLM | |
| 650 | 7 | |a Antibodies, Monoclonal |2 NLM | |
| 700 | 1 | |a Swanson, Michael |e verfasserin |4 aut | |
| 700 | 1 | |a Sullivan, Nicole |e verfasserin |4 aut | |
| 700 | 1 | |a Homan, Ying |e verfasserin |4 aut | |
| 700 | 1 | |a Nahas, Debbie |e verfasserin |4 aut | |
| 700 | 1 | |a Mukhopadhyay, Shreya |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Hualin Helen |e verfasserin |4 aut | |
| 700 | 1 | |a Cao, Yu |e verfasserin |4 aut | |
| 700 | 1 | |a Xu, Weifeng |e verfasserin |4 aut | |
| 700 | 1 | |a Tang, Huaping |e verfasserin |4 aut | |
| 700 | 1 | |a Vora, Kalpit A |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Zhifeng |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Bioanalysis |d 2009 |g 15(2023), 16 vom: 29. Aug., Seite 1049-1067 |w (DE-627)NLM196969840 |x 1757-6199 |7 nnns |
| 773 | 1 | 8 | |g volume:15 |g year:2023 |g number:16 |g day:29 |g month:08 |g pages:1049-1067 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.4155/bio-2023-0081 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 15 |j 2023 |e 16 |b 29 |c 08 |h 1049-1067 | ||